354 results on '"Nimmagadda, Sridhar"'
Search Results
2. Correction: Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with 89Zirconium oxine for PET imaging
3. Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with 89Zirconium oxine for PET imaging
4. PET/Computed Tomography Transformation of Oncology: Kidney and Urinary Tract Cancers
5. Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia
6. Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics
7. CD38‐Specific Gallium‐68 Labeled Peptide Radiotracer Enables Pharmacodynamic Monitoring in Multiple Myeloma with PET
8. Preclinical Experimentation in Oncology
9. Non-invasive PD-L1 quantification using [18F]DK222-PET imaging in cancer immunotherapy
10. Peptide-based PET quantifies target engagement of PD-L1 therapeutics
11. PET/MRI and Bioluminescent Imaging Identify Hypoxia as a Cause of Programmed Cell Death Ligand 1 Image Heterogeneity
12. A Gallium-68-Labeled Peptide Radiotracer For CD38-Targeted Imaging In Multiple Myeloma With PET
13. Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy
14. A PSMA-targeted theranostic agent for photodynamic therapy
15. Comparison of skeletal and soft tissue pericytes identifies CXCR4+ bone forming mural cells in human tissues
16. Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with 89Zirconium oxine for PET imaging.
17. Molecular Imaging of CXCL12 Promoter-driven HSV1-TK Reporter Gene Expression
18. Abstract 2768: Non-invasive detection of pancreatic adenocarcinoma using Ga-68 labelled epha2 targeting peptide
19. Supplementary Figure S5 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
20. Data from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
21. Data from 2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer
22. Supplementary Figure 2 from 2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer
23. Supplementary Methods, Figure 3 from 2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer
24. Supplementary Figure 1 from 2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer
25. Supplementary Methods, Figures 1-3 from Molecular Imaging of CXCR4 Receptor Expression in Human Cancer Xenografts with [64Cu]AMD3100 Positron Emission Tomography
26. Data from Molecular Imaging of CXCR4 Receptor Expression in Human Cancer Xenografts with [64Cu]AMD3100 Positron Emission Tomography
27. Supplementary Movie 1 from Molecular Imaging of CXCR4 Receptor Expression in Human Cancer Xenografts with [64Cu]AMD3100 Positron Emission Tomography
28. Supplementary Movie Legend from Molecular Imaging of CXCR4 Receptor Expression in Human Cancer Xenografts with [64Cu]AMD3100 Positron Emission Tomography
29. SNP2SIM: a modular workflow for standardizing molecular simulation and functional analysis of protein variants
30. An optimized radiosynthesis of [ 18 F]DK222, a PET radiotracer for imaging PD‐L1
31. Decoupling Fcrn and Tumor Contributions to Elevated Immune Checkpoint Inhibitor Clearance in Cancer Cachexia
32. Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
33. Imaging α4β2 Nicotinic Acetylcholine Receptors (nAChRs) in Baboons with [18F]XTRA, a Radioligand with Improved Specific Binding in Extra-Thalamic Regions
34. Molecular Imaging of CXCR4 Receptor Expression in Tumors
35. Abstract 2481: Imaging pancreatic ductal adenocarcinoma using an EphA2 receptor tyrosine kinase binding 68Ga-labeled peptide radiotracer
36. Abstract 2477: PD-L1 PET quantifies the pharmacodynamic effects of immunotherapy
37. An optimized radiosynthesis of [18F]DK222, a PET radiotracer for imaging PD‐L1.
38. Distribution of Cell-Free and Cell-Associated HIV Surrogates in the Female Genital Tract After Simulated Vaginal Intercourse
39. PD-L1 near Infrared Photoimmunotherapy of Ovarian Cancer Model
40. Imaging PD-L1 expression in melanoma brain metastases
41. Process validation, cGMP production, dosimetry, and toxicity studies of the CAIX imaging agent [(111)In]XYIMSR-01 for phase I regulatory approval
42. The Intricate Role of CXCR4 in Cancer
43. First-in-Humans Evaluation of a PD-L1–Binding Peptide PET Radiotracer in Non–Small Cell Lung Cancer Patients
44. Herpes simplex virus thymidine kinase imaging in mice with (1-(2′-deoxy-2′-[18F]fluoro-1-β-D-arabinofuranosyl)-5-iodouracil) and metabolite (1-(2′-deoxy-2′-[18F]fluoro-1-β-D-arabinofuranosyl)-5-uracil)
45. The role of DNA synthesis imaging in cancer in the era of targeted therapeutics
46. Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules
47. Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [111In]In‐XYIMSR‐01 for phase I regulatory approval
48. Molecular Imaging of CXCR4 Receptor Expression in Tumors
49. Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges
50. Abstract 3448: A highly specific 18F-labelled peptide for non-invasive quantification of PD-L1 levels in tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.